KIR2DL1產(chǎn)品信息
英文名稱:Killer cell immunoglobulin-like receptor 2DL1
中文名稱:殺傷細(xì)胞免疫球蛋白樣受體2DL1
靶點(diǎn)別稱:KIR2DL1,CD158a
物種:Human
標(biāo)簽:Fc Tag
屬性:Protein
標(biāo)記:Unconjugated
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human KIR2DL1, Fc Tag (KI1-H5255) is expressed from human 293 cells (HEK293). It contains AA His 22 - Arg 242 (Accession # P43626-1).
Predicted N-terminus: His 22
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 50.7 kDa. The protein migrates as 60-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

背景(Background)
殺傷細(xì)胞免疫球蛋白樣受體2DL1(KIR2DL1)屬于免疫球蛋白超家族,是NK細(xì)胞的抑制性受體。NK細(xì)胞活性的調(diào)節(jié)是通過(guò)殺傷細(xì)胞免疫球蛋白樣受體(KIR)識(shí)別人類(lèi)白細(xì)胞抗原(HLA)I類(lèi)分子作為配體的能力來(lái)介導(dǎo)的。KIR和HLA的相互作用與病毒感染、自身免疫和生殖有關(guān),越來(lái)越多的證據(jù)表明這兩個(gè)獨(dú)立分離的基因家族是共同進(jìn)化的。KIR2DL1與β-arrestin 2的關(guān)聯(lián)介導(dǎo)酪氨酸磷酸酶SHP-1和SHP-2向KIR2GL1的募集,并促進(jìn)下游抑制信號(hào)傳導(dǎo)。
關(guān)鍵字: KIR2DL1;KIR2DL1蛋白;KIR2DL1重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。